MingSight is a clinical-stage company focused on developing differentiated therapies for B-cell malignancies, DME, and autoimmune diseases. Its lead investigational candidate, MS-553, is a novel PKC beta inhibitor with a chemotype that the company says offers improved selectivity, safety, and pharmacokinetic properties versus prior pan‑PKC inhibitors. MS-553 has shown proof of mechanism and promising efficacy and safety in a phase 1/2 study in CLL patients, including those with BTK-resistant C481S and PLCG2 mutations, and demonstrated reductions in retinal thickness and improvements in visual acuity in a phase 1b DME trial. A notable PK property is MS-553's preferential distribution to the retina after oral dosing, supporting its potential as a non‑invasive oral alternative to intravitreal anti‑VEGF injections. MingSight plans to use the new financing to accelerate clinical development of MS-553 in both CLL and DME. The company is headquartered in San Diego, California.

Total raised

$20M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2021